Equities analysts expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report earnings of ($0.21) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.21). Pieris Pharmaceuticals reported earnings of ($0.14) per share during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.84) to ($0.82). For the next year, analysts anticipate that the company will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.86) to ($0.83). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Pieris Pharmaceuticals.

Several brokerages have recently commented on PIRS. Rodman & Renshaw began coverage on shares of Pieris Pharmaceuticals in a research note on Tuesday, May 30th. They set a “buy” rating and a $9.00 price target on the stock. BidaskClub lowered shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 26th. HC Wainwright set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th. Finally, TheStreet lowered shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research note on Monday, June 12th. Five equities research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $8.25.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 5.33 on Friday. The company’s 50 day moving average is $5.17 and its 200 day moving average is $3.98. Pieris Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.20. The firm’s market cap is $236.16 million.

In other Pieris Pharmaceuticals news, insider Allan Reine purchased 65,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $4.82 per share, for a total transaction of $313,300.00. Following the purchase, the insider now directly owns 45,000 shares in the company, valued at approximately $216,900. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $48,200. The disclosure for this purchase can be found here. Corporate insiders own 4.05% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning increased its stake in shares of Pieris Pharmaceuticals by 8.3% during the 2nd quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock worth $329,000 after purchasing an additional 5,000 shares during the last quarter. Voya Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $100,000. State of Wisconsin Investment Board acquired a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $132,000. The Manufacturers Life Insurance Company increased its stake in shares of Pieris Pharmaceuticals by 1,106.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 29,150 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $162,000. Institutional investors own 50.55% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.21 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/09/pieris-pharmaceuticals-inc-pirs-expected-to-post-earnings-of-0-21-per-share.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.